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NEEDS IN TUBERCULOSIS RESEARCH*
R. Prabhakar1
Tuberculosis is still a major health problem
in developing countries. It is also emerging as
a major infectious disease in the developed
countries due to AIDS epidemic. Its pathogenesis,
immunology and molecular biology are still
incompletely understood. The development of
new drugs to fight tuberculosis ceased over two
decades ago. The variable efficacy of BCG,
found in different trials, still remains an enigma.
And, it is likely that its epidemiology is also
different, in some aspects, in developing countries
compared with the developed ones. Sometime
ago, it was said that the application of current
knowledge about tuberculosis was lagging so far
behind its application in the field that the focus
should shift from more and more research in
tuberculosis. That saying appears to have lost its
validity under the present circumstances, especially
when the WHO has declared a global war on the
“neglected epidemic”. The following horizons in
different aspects of tuberculosis can be recognised
in respect of research needs in tuberculosis.
Epidemiology
Infection
Setting up of surveillance systems to assess
the impact of control programmes. Monitoring of
changes in tuberculosis infection (or prevalence
of infection) (a) Sequential tuberculin testing
surveys among children; (b) Surveys among
sentinel populations of young adults.
Disease
Case control studies to identify the factors
responsible for progression of disease. Application
of new methods to characterise strains of tubercle
bacilli - DNA fingerprinting. Studies to determine
the impact of HIV infection on TB. Tuberculin
surveys amongst close contacts of tuberculosis
cases. Effect of preventive chemotherapy on the
infectiousness.
Diagnosis (Case-Finding)
1.
2.
3.
4.
Improvement of case-finding:
KAP studies on tuberculosis
Integration of tuberculosis services into
primary health case
Health Education
Active case-finding focussed on high risk
populations
Improvingthe diagnosis among patients
presenting at health care facilities.
Increased involvement of private practitioners
and traditional healers
Improvement in currently used technologies:
- Improvement in smear microscopy
- Slide cultures
- Improved culture techniques, including
development of a simple non-
radiometric technique of detecting
mycobacteria prior to visible growth
Development and in-service evaluation of
new technologies for the diagnosis and
pred ic t i on  o f :
(a) early disease;
(b) relapse;
(c) prognosis of tuberculosis, that have
potentially
(i) greater sensitivity
(ii) higher specificity
(iii) greater rapidity
(iv) greater cost effectiveness, and
(v) greater applicability to developing
countries
Improved methods for diagnosis of M.
tuberculosis nfections. The criteria required
for a new diagnostic test include
(1) Cost-should be less than US $ 0.50
per test
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(2) Speed-result should be available within M. tuberculosis, M.bovis, M.microti and
two hours M. africcanum.
(3) Sensitivity and specificity - should be
99% when compared with culture
Treatment and Case Holding.
(4) Simplicity-should be adaptable to use
in field conditions in developing
countries
Improvement of patient adherence to
treatment crucial in developing countries.
1. Studies to improve
(5)  Reliability and reproducibility
(6) Safety and acceptability to both users
and providers
the present delivery system of
chemotherapy
(7) Not invasive (short of a finger stick)
(8) “User friendly”
5. Approaches in development of new diagnostic
test(s):
alternatives to hospitalization
DOT (directly observed therapy) in the
initial intensive phase of SCC
novel drug delivery (e.g. calendar, blister
packs)
(a) Detection of the response of the host
to t h e  b a c i l l i .  T h e  f i r s t
immunodiagnostic tuberculin test is
unable to distinguish active tuberculosis
from past sensitisation, BCG
vaccination or environmental
mycobacteria.
impact of participation by the private
sector
community participation
2. Studies to
- improve treatment adherence
- evaluate incentives and enablers
- select potentially non-adherent patients
for supervised chemotherapy
(b) Serologic tests are based on the binding
of an antigen to its specific antibody
in serum. ELISA test is the choicest
of all serological tests.
3. Cost-effectiveness analyses of various
regimens of SCC.
(c) A very high specificity is required for
any new test to be applied to the
patients of mycobacterial disease. In
competent laboratories, the existing
methods of sputum microscopy and
culture have specificities approaching
1, and this sets the standard that must
be matched by new diagnostic tests.
The specificity of immunodiagnosis
depends on the specificity of the
antigens and antibodies used.
Diagnostic PCR is a technique of
DNA amplification that uses specific
DNA sequences to serve as markers
for the presence of micro-organisms.
The genetic marker most commonly
used is mycobacterial insertion element
- IS 6110 - DNA piece of uncertain
functional sequence present in
4.
5.
Surveys of consumer satisfaction
Surveillance of initial resistence to Isoniazid,
Streptomycin, Rifampicin and Ethambutol
6. Development of new therapeutic modalities:
New drugs like
Long acting Rifamycins: Rifapentene,
Rifabutin
Quinolones: Ofloxacin, Ciprofloxacin;
Sparfloxacin.
B lactamhse inhibitors: Amoxycillin,
Ticarcillin and Clavulanic acid
Newer Aminoglycosides
Clofazimine
Prevention
1. Efficacy and operational studies, including
analysis of cost-effectiveness to define the
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2.
3.
4.
5.
role of preventive chemotherapy in high-
risk populations.
despite the continuing heavy burden of
disease
Revaccination with BCG vaccine
New forms of preventive therapy, new
drugs, immunotherapeutics, depot
preparations
Development and testing new anti-
tuberculosis vaccines including understanding
the immunology and molecular biology of
the bacillus
ineffective negotiations for low-priced
purchase of drugs, and poorly managed
distribution and quality control system
incomplete management information
system
lack of control over prescribing and sale
leading to drug resistance and chronic
excreters
Additional studies with BCG:
Neonatal vaccination, studies of additives
to BCG (e.g.killed M. vaccae); safety of
BCG vaccine in HIV infected persons.
poorly planned and executed integration
of tuberculosis control programmes into
primary health care systems, including
lack of supervision and training
lack of health services management
Economic, Social and Operational Research
1. Problems at the Tuberculosis Clinic level:
- inadequately trained, poorly supervised
and over-burdened, health manpower
- incorrect or incomplete information
available to the public on tuberculosis
symptoms and risks
-  deficiencies in the quality of diagnosis,
despite efficacious technology
  - inadequate cooperation and referral
arrangements with private providers of
services
-   Poorly designed or completed registries
and notification forms
- drug supply problems leading to
intermittent shortages
-  improper prescribing patterns, and lack
of follow-up
- difficulties in motivating patients and
ensuring compliance
- lack of staff, transport and information
systems to follow up all patients who do
not adhere to treatment.
2. At the national or provincial control
programme levels
- increasing competition for scarce health
sector financial resources
- the low-priority status for tuberculosis
3.
4.
How to
make efficient and effective use of existing
technologies
improve the delivery system infrastructure
increase patient and provider motivation
and compliance
appropriately adapt new technologies to
operational settings
expand programme coverage
increase political and financial support for
tuberculosis control efforts
Studies focussed on
cost-effective diagnostic and treatment
strategies that are appropriate and feasible
improvement of health service infrastructures
for tuberculosis control
role of hospitals in tuberculosis diagnosis
and treatment
development of strategies for enhancing the
cost-effective use of hospitals
scope of private sector involvement in
diagnosis and treatment (including traditional
healers)
KAP of providers
development of models for integrating
tuberculosis control into related control
services.
